Please check your internet connection and try again.
# Dexamethasone in Chronic ITP
## Overview
Dexamethasone is a potent synthetic glucocorticoid with minimal mineralocorticoid activity. In Immune Thrombocytopenia (ITP), it is utilized for its rapid immunomodulatory effects, promoting platelet production and inhibiting the reticuloendothelial system's clearance of antibody-coated platelets.
## Primary Indications
First-line treatment for newly diagnosed ITP to increase platelet counts; occasionally used for relapsed or refractory chronic ITP as a pulse therapy.
## Adult Dosing
* **Standard Pulse Regimen:** 40 mg orally once daily for 4 consecutive days.
* **Cycles:** May repeat every 14–28 days depending on platelet response and clinical judgment.
* **Max Dose:** 40 mg/day.
## Pediatric Dosing
Dosing is highly dependent on institutional protocols (e.g., ASH guidelines).
* **Standard Pulse Regimen:** 0.6 mg/kg/day (maximum 40 mg/day) orally once daily for 4 consecutive days.
* **Cycles:** Repeat cycles as guided by hematology/oncology protocols.
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be reduced; monitor for increased toxicity.
* **Elderly:** Use caution; lower doses or extended intervals may be required due to increased sensitivity to steroid side effects (e.g., hyperglycemia, psychiatric effects).
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or components of the formulation.
* Cerebral malaria (may be harmful).
## Adverse Effects
* **Common:** Insomnia, agitation, mood swings, hyperglycemia, increased appetite, fluid retention.
* **Serious:** Gastritis/peptic ulcer disease, immunosuppression, hypertension, aseptic necrosis of the bone (typically with chronic use), secondary adrenal insufficiency.
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., phenytoin, phenobarbital, rifampin) decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors:** (e.g., ketoconazole, clarithromycin, ritonavir) increase dexamethasone exposure.
* **NSAIDs/Aspirin:** Increased risk of gastrointestinal ulceration/bleeding.
* **Vaccines:** Avoid live vaccines due to potential immunosuppression.
## Monitoring
* **Baseline:** CBC with differential, blood glucose, blood pressure, and mental health screening.
* **Ongoing:** Monitor platelet counts to assess response (usually peaks 7–14 days post-cycle). Monitor glucose levels in diabetic patients.
## Clinical Pearls
* **Efficacy:** High-dose pulse dexamethasone often yields a faster initial platelet count rise compared to standard-dose prednisone, though durability of response varies.
* **Administration:** Administer with food to minimize GI upset.
* **Psychiatric Safety:** Warn patients and caregivers about potential mood swings or insomnia, which are frequently reported with high-dose pulses.
* **Uncertainty:** There is no universally defined "standard" for the number of repeat cycles in chronic ITP; strategy should be individualized by an hematologist based on bleeding risk and platelet stability.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution; always verify current prescribing information, local clinical guidelines, and specific patient contraindications before administering medication.
